Login to Your Account

Alkermes Maps Out Growth Plan with Expanded Portfolio

By Cormac Sheridan

Wednesday, July 20, 2011
DUBLIN, Ireland – With its $960 million cash-and-shares acquisition of Elan Drug Technologies (EDT) slated to close in the current quarter, Alkermes Inc. spent Monday afternoon bringing analysts and investors up to speed on how to model the soon-to-be-enlarged company and on where to look for the double-digit growth it has set its sights on. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription